☰

Holly Janes, Ph.D. - Publications

Affiliations: 
2005 University of Washington, Seattle, Seattle, WA 
Area:
Statistics, Public Health
Tree Info Similar researchers PubMed Report error

49 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Marsh TL, Janes H, Pepe MS. Statistical inference for net benefit measures in biomarker validation studies. Biometrics. PMID 31732971 DOI: 10.1111/Biom.13190  0.597
2019 Li SS, Gilbert PB, Carpp LN, Pyo CW, Janes H, Fong Y, Shen X, Neidich SD, Goodman D, deCamp A, Cohen KW, Ferrari G, Hammer SM, Sobieszczyk ME, Mulligan MJ, et al. Fc gamma receptor polymorphisms modulated the vaccine effect on HIV-1 risk in the HVTN 505 HIV vaccine trial. Journal of Virology. PMID 31434737 DOI: 10.1128/Jvi.02041-18  0.301
2019 Kerr KF, Brown MD, Marsh TL, Janes H. Assessing the Clinical Impact of Risk Models for Opting Out of Treatment. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 272989X18819479. PMID 30649998 DOI: 10.1177/0272989X18819479  0.392
2018 Kang C, Janes H, Tajik P, Groen H, Mol B, Koopmans C, Broekhuijsen K, Zwertbroek E, van Pampus M, Franssen M. Evaluation of biomarkers for treatment selection using individual participant data from multiple clinical trials. Statistics in Medicine. PMID 29444553 DOI: 10.1002/Sim.7608  0.397
2017 Kerr KF, Janes H. First things first: risk model performance metrics should reflect the clinical application. Statistics in Medicine. 36: 4503-4508. PMID 29156498 DOI: 10.1002/Sim.7341  0.434
2017 Dai JY, Liang CJ, LeBlanc M, Prentice RL, Janes H. Case-only approach to identifying markers predicting treatment effects on the relative risk scale. Biometrics. PMID 28960244 DOI: 10.1111/Biom.12789  0.405
2016 Kerr KF, Brown MD, Zhu K, Janes H. Assessing the Clinical Impact of Risk Prediction Models With Decision Curves: Guidance for Correct Interpretation and Appropriate Use. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27247223 DOI: 10.1200/Jco.2015.65.5654  0.371
2016 Pepe MS, Janes H, Li CI, Bossuyt PM, Feng Z, Hilden J. Early-Phase Studies of Biomarkers: What Target Sensitivity and Specificity Values Might Confer Clinical Utility? Clinical Chemistry. PMID 27001493 DOI: 10.1373/Clinchem.2015.252163  0.517
2016 Urban N, Hawley S, Janes H, Karlan BY, Drescher CW, Daly MB, Anderson GL. Abstract IA20: Biomarkers for risk prediction, screening, and early diagnostics. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-Ia20  0.399
2015 Urban N, Hawley S, Janes H, Karlan BY, Berg CD, Drescher CW, Manson JE, Palomares MR, Daly MB, Wactawski-Wende J, O'Sullivan MJ, Thorpe J, Robinson RD, Lane D, Li CI, et al. Identifying post-menopausal women at elevated risk for epithelial ovarian cancer. Gynecologic Oncology. PMID 26343159 DOI: 10.1016/J.Ygyno.2015.08.024  0.347
2015 Huang Y, Follmann D, Nason M, Zhang L, Huang Y, Mehrotra DV, Moodie Z, Metch B, Janes H, Keefer MC, Churchyard G, Robb ML, Fast PE, Duerr A, McElrath MJ, et al. Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials. Plos One. 10: e0136626. PMID 26332672 DOI: 10.1371/Journal.Pone.0136626  0.319
2015 Janes H, Brown MD, Pepe MS. Designing a study to evaluate the benefit of a biomarker for selecting patient treatment. Statistics in Medicine. PMID 26112650 DOI: 10.1002/Sim.6564  0.562
2015 Janes H, Pepe MS, McShane LM, Sargent DJ, Heagerty PJ. The Fundamental Difficulty With Evaluating the Accuracy of Biomarkers for Guiding Treatment. Journal of the National Cancer Institute. 107. PMID 26109106 DOI: 10.1093/Jnci/Djv157  0.541
2015 Huang Y, Laber EB, Janes H. Characterizing expected benefits of biomarkers in treatment selection. Biostatistics (Oxford, England). 16: 383-99. PMID 25190512 DOI: 10.1093/Biostatistics/Kxu039  0.382
2014 Li SS, Gilbert PB, Tomaras GD, Kijak G, Ferrari G, Thomas R, Pyo CW, Zolla-Pazner S, Montefiori D, Liao HX, Nabel G, Pinter A, Evans DT, Gottardo R, Dai JY, ... Janes H, et al. FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. The Journal of Clinical Investigation. 124: 3879-90. PMID 25105367 DOI: 10.1172/Jci75539  0.302
2014 Kang C, Janes H, Huang Y. Rejoinder: Combining biomarkers to optimize patient treatment recommendations. Biometrics. 70: 719-20. PMID 24889787 DOI: 10.1111/Biom.12192  0.382
2014 Kang C, Janes H, Huang Y. Combining biomarkers to optimize patient treatment recommendations. Biometrics. 70: 695-707. PMID 24889663 DOI: 10.1111/Biom.12191  0.381
2014 Janes H, Brown MD, Huang Y, Pepe MS. An approach to evaluating and comparing biomarkers for patient treatment selection. The International Journal of Biostatistics. 10: 99-121. PMID 24695044 DOI: 10.1515/Ijb-2012-0052  0.587
2014 Pepe MS, Janes H, Li CI. Net risk reclassification p values: valid or misleading? Journal of the National Cancer Institute. 106: dju041. PMID 24681599 DOI: 10.1093/Jnci/Dju041  0.605
2014 Kerr KF, Wang Z, Janes H, McClelland RL, Psaty BM, Pepe MS. Net reclassification indices for evaluating risk prediction instruments: a critical review. Epidemiology (Cambridge, Mass.). 25: 114-21. PMID 24240655 DOI: 10.1097/Ede.0000000000000018  0.602
2014 Janes H, Pepe MS, Huang Y. A framework for evaluating markers used to select patient treatment. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 34: 159-67. PMID 23811760 DOI: 10.1177/0272989X13493147  0.617
2013 Janes H, Gilbert P, Buchbinder S, Kublin J, Sobieszczyk ME, Hammer SM. In pursuit of an HIV vaccine: designing efficacy trials in the context of partially effective nonvaccine prevention modalities. Aids Research and Human Retroviruses. 29: 1513-23. PMID 23597282 DOI: 10.1089/Aid.2012.0385  0.303
2013 Janes H, Pepe M. Re: "Clinical usefulness of the Framingham cardiovascular risk profile beyond its statistical performance: the Tehran Lipid and Glucose Study". American Journal of Epidemiology. 177: 864-5. PMID 23524037 DOI: 10.1093/Aje/Kwt043  0.555
2013 Pepe M, Janes H. Methods for evaluating prediction performance of biomarkers and tests Lecture Notes in Statistics. 215: 107-142. DOI: 10.1007/978-1-4614-8981-8_7  0.57
2012 Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, ... ... Janes H, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. The New England Journal of Medicine. 366: 1275-86. PMID 22475592 DOI: 10.1056/Nejmoa1113425  0.315
2012 Huang Y, Gilbert PB, Janes H. Assessing treatment-selection markers using a potential outcomes framework. Biometrics. 68: 687-96. PMID 22299708 DOI: 10.1111/j.1541-0420.2011.01722.x  0.317
2011 Pepe MS, Janes H. Commentary: Reporting standards are needed for evaluations of risk reclassification. International Journal of Epidemiology. 40: 1106-8. PMID 21571811 DOI: 10.1093/Ije/Dyr083  0.615
2011 Janssens AC, Ioannidis JP, Bedrosian S, Boffetta P, Dolan SM, Dowling N, Fortier I, Freedman AN, Grimshaw JM, Gulcher J, Gwinn M, Hlatky MA, Janes H, Kraft P, Melillo S, et al. Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration. European Journal of Clinical Investigation. 41: 1010-35. PMID 21434890 DOI: 10.1111/J.1365-2362.2011.02493.X  0.381
2011 Janssens AC, Ioannidis JP, Bedrosian S, Boffetta P, Dolan SM, Dowling N, Fortier I, Freedman AN, Grimshaw JM, Gulcher J, Gwinn M, Hlatky MA, Janes H, Kraft P, Melillo S, et al. Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration. European Journal of Epidemiology. 26: 313-37. PMID 21424820 DOI: 10.1007/S10654-011-9551-Z  0.38
2011 Janssens AC, Ioannidis JP, Bedrosian S, Boffetta P, Dolan SM, Dowling N, Fortier I, Freedman AN, Grimshaw JM, Gulcher J, Gwinn M, Hlatky MA, Janes H, Kraft P, Melillo S, et al. Strengthening the reporting of Genetic RIsk Prediction Studies (GRIPS): explanation and elaboration. Journal of Clinical Epidemiology. 64: e1-e22. PMID 21414753 DOI: 10.1016/J.Jclinepi.2011.02.003  0.38
2011 Janssens AC, Ioannidis JP, Bedrosian S, Boffetta P, Dolan SM, Dowling N, Fortier I, Freedman AN, Grimshaw JM, Gulcher J, Gwinn M, Hlatky MA, Janes H, Kraft P, Melillo S, et al. Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration. European Journal of Human Genetics : Ejhg. 19: 18 p preceding 494. PMID 21407270 DOI: 10.1038/Ejhg.2011.27  0.38
2011 Janes H, Pepe MS, Bossuyt PM, Barlow WE. Measuring the performance of markers for guiding treatment decisions. Annals of Internal Medicine. 154: 253-9. PMID 21320940 DOI: 10.7326/0003-4819-154-4-201102150-00006  0.58
2010 Janes H, Dominici F, Zeger S. On quantifying the magnitude of confounding. Biostatistics (Oxford, England). 11: 572-82. PMID 20203259 DOI: 10.1093/Biostatistics/Kxq007  0.304
2009 Janes H, Pepe MS. Adjusting for covariate effects on classification accuracy using the covariate-adjusted receiver operating characteristic curve. Biometrika. 96: 371-382. PMID 22822245 DOI: 10.1093/Biomet/Asp002  0.576
2009 Pepe M, Longton G, Janes H. Estimation and Comparison of Receiver Operating Characteristic Curves. The Stata Journal. 9: 1. PMID 20161343 DOI: 10.1177/1536867X0900900101  0.577
2009 Janes H, Longton G, Pepe M. Accommodating Covariates in ROC Analysis. The Stata Journal. 9: 17-39. PMID 20046933  0.553
2009 Janes H, Longton G, Pepe MS. Accommodating covariates in receiver operating characteristic analysis Stata Journal. 9: 17-39. DOI: 10.1177/1536867X0900900102  0.591
2009 Janes H, Pepe MS, Gu W. In response Annals of Internal Medicine. 150: 428.  0.408
2008 Janes H, Pepe MS, Gu W. Assessing the value of risk predictions by using risk stratification tables. Annals of Internal Medicine. 149: 751-60. PMID 19017593 DOI: 10.7326/0003-4819-149-10-200811180-00009  0.673
2008 Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. Journal of the National Cancer Institute. 100: 1432-8. PMID 18840817 DOI: 10.1093/Jnci/Djn326  0.595
2008 Pepe MS, Janes HE. Gauging the performance of SNPs, biomarkers, and clinical factors for predicting risk of breast cancer. Journal of the National Cancer Institute. 100: 978-9. PMID 18612128 DOI: 10.1093/Jnci/Djn215  0.574
2008 Janes H, Pepe MS. Adjusting for covariates in studies of diagnostic, screening, or prognostic markers: an old concept in a new setting. American Journal of Epidemiology. 168: 89-97. PMID 18477651 DOI: 10.1093/Aje/Kwn099  0.577
2008 Janes H, Pepe MS. Matching in studies of classification accuracy: implications for analysis, efficiency, and assessment of incremental value. Biometrics. 64: 1-9. PMID 17501939 DOI: 10.1111/J.1541-0420.2007.00823.X  0.592
2007 Pepe MS, Janes H, Gu JW. Letter by Pepe et al regarding article, "Use and misuse of the receiver operating characteristic curve in risk prediction". Circulation. 116: e132; author reply e. PMID 17679623 DOI: 10.1161/Circulationaha.107.709253  0.611
2007 Pepe MS, Janes H. Insights into latent class analysis of diagnostic test performance. Biostatistics (Oxford, England). 8: 474-84. PMID 17085745 DOI: 10.1093/Biostatistics/Kxl038  0.552
2006 Lumley T, Janes H, Sheppard L. Cox models for ecologic time-series data? Environmental Health Perspectives. 114: A690-1; author reply. PMID 17185253 DOI: 10.1289/Ehp.114-1764157  0.35
2006 Janes H, Pepe M. The optimal ratio of cases to controls for estimating the classification accuracy of a biomarker. Biostatistics (Oxford, England). 7: 456-68. PMID 16428259 DOI: 10.1093/Biostatistics/Kxj018  0.567
2005 Janes H, Pepe M, Kooperberg C, Newcomb P. Identifying target populations for screening or not screening using logic regression. Statistics in Medicine. 24: 1321-38. PMID 15568185 DOI: 10.1002/Sim.2021  0.56
2004 Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. American Journal of Epidemiology. 159: 882-90. PMID 15105181 DOI: 10.1093/Aje/Kwh101  0.555
Show low-probability matches.